Meagan Parrish from Pharma Voice - Journalist Profile

	Profile	Contacts	Recent Articles on Subject
1	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting		Will the ‘anti-woke’ movement derail DEI efforts in pharma? - 7 days ago What’s next for 23andMe? - 10 days ago Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide - 11 days ago Trump’s tariffs could put more pressure on the U.S. to produce generic drugs. Are we ready? - 14 days ago The big rebrand: Why these 4 biopharmas changed their name this year - 16 days ago Note from the Editor-in-Chief - 18 days ago Can the girl power of Arrivo’s depression drug help reverse its fortunes? - 18 days ago Will Walgreens’ store closures derail its clinical trial aims? - 28 days ago The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - about 1 month ago Where are they now? 4 biotechs that soared then crashed during the pandemic - about 1 month ago Spravato is just the beginning in a new wave of depression meds - about 1 month ago CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure - about 2 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - about 2 months ago A sickle cell cure exists. But patients need more than just gene therapy. - about 2 months ago 2024 PharmaVoice 100s: Rare Disease Warriors - about 2 months ago On the front lines of the superbug war, new treatments can’t arrive soon enough - about 2 months ago J&J’s comeback kid Spravato heads for blockbuster status - about 2 months ago Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next? - about 2 months ago 2024 PharmaVoice 100s: Patient Champions - about 2 months ago Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with - 2 months ago 2024 PharmaVoice 100s: Trailblazers - 2 months ago Want to launch a blockbuster? An AstraZeneca exec breaks it down. - 2 months ago 2024 PharmaVoice 100s: Standout Leaders - 2 months ago BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s - 2 months ago An Alzheimer’s drugmaker is accused of data ‘manipulation.’ Should its trials be stopped? - 3 months ago California is a life sciences leader. Joe Panetta has been one of its most vocal advocates. - 3 months ago After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? - 3 months ago Who’s winning in biotech’s tight market? - 3 months ago Why pharma should redefine ‘women’s health’ - 3 months ago What 3 layoff stories reveal about pharma’s troubles - 4 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 4 months ago Is anyone taking the world’s priciest drugs? - 4 months ago What pharma has learned from AI - 5 months ago Neuro drugs are still faltering, despite rising investment - 5 months ago Bird flu puts BARDA back in the spotlight - 5 months ago Amylyx’s CEOs on their ALS setback and quest to revamp the pipeline - 5 months ago Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - 5 months ago Up-and-comers look for an edge in the bustling ADC field - 6 months ago Pfizer’s Paxlovid flunks long COVID study as researchers uncover the condition’s deep toll - 6 months ago Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 6 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 7 months ago Where competition is heating up in pharma - 7 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 7 months ago Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma - 8 months ago As BMS announces major cuts, its Karuna deal looks poised to drive growth - 8 months ago 3 big recent trial flops - 8 months ago Viral return: 3 U.S. cases concerning experts - 9 months ago The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle - 9 months ago GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that. - 9 months ago After Amylyx drug failure, what’s next for ALS? - 9 months ago